Terms: = Cervical cancer AND MYO5A, Q9Y4I1, MYR12, MYO5, MYH12, GS1, ENSG00000197535, 4644 AND Treatment
1 results:
1. Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis.
Barrington DA; Riedinger C; Haight PJ; Tubbs C; Cohn DE
Gynecol Oncol; 2022 Jun; 165(3):500-505. PubMed ID: 35422338
[TBL] [Abstract] [Full Text] [Related]
